July 14, 2021 -- Eli Lilly will acquire private biotechnology firm Protomer Technologies for an estimated $1 billion.
Protomer engineers next-generation protein therapies that can sense molecular activators in the body. Its chemical biology-based platform enables the development of therapeutic peptides and proteins, including glucose-responsive insulins, with tunable activity that can be controlled with small molecules.
The potential value of the transaction could total more than $1 billion with future development and commercial milestones.